![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Novartis Retains Top Spot in CNS Summit Innovation Index
Novartis Retains Top Spot in CNS Summit Innovation Index
December 5, 2019
For the second year in a row Novartis has been named the most innovative pharma company by the Innovation Index, a collaboration between CNS Summit and IDEA Pharma.
In digital innovation, Novartis moved up to place first from the middle of the pack on the basis of its use of artificial intelligence (AI) to wield big data more effectively.
“The differentiator between Novartis and the competition was the nature of these innovative initiatives, which showed strong potential to be transformative, rather than incremental,” said a report on the index, which measures companies’ advances in trial optimization, clinical innovation and use of digital technology.
Novartis was second in clinical trial innovation with accolades for its partnership with the Massachusetts Institute of Technology, in which it used wireless technology for passive, contactless monitoring of physiological signals. It also ranked second in the trial optimization category.
Upcoming Events
-
21Oct